Editing Tissue engineering (section)

=== Reemergence ===
The technologies of the bankrupt or struggling companies were often bought by other companies which continued the development under more conservative business models.<ref name=":3" /> Examples of companies who sold their products after folding were Curis<ref name=":3" /> and Intercytex.<ref name="Umemura2019" />

Many of the companies abandoned their long-term goals of developing fully functional organs in favor of products and technologies that could turn a profit in the short run.<ref name="Umemura2019" /> Examples of these kinds of products are products in the cosmetic and testing industry.

In other cases such as in the case of Advanced Tissue Sciences, the founders started new companies.<ref name="Umemura2019" />

In the 2010s the regulatory framework also started to facilitate faster time to market especially in the US as new centres and pathways were created by the FDA specifically aimed at products coming from living cells such as the [[Center for Biologics Evaluation and Research]].<ref name="Umemura2019" />

The first tissue engineering products started to get commercially profitable in the 2010s.<ref name=":3" />